Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2025 Mar 20:43:101207.
doi: 10.1016/j.ymgmr.2025.101207. eCollection 2025 Jun.

Successful desensitization protocol to alglucosidase and avalglucosidase alfa in a patient with infantile-onset Pompe disease

Miriam Gendive  1 , Teresa C Delgado  2   3 , María Unceta  2   4 , Arantza Arza  2   4 , Beatriz Sordo  2   5 , Aritza Segurola  2   6 , Javier De Las Heras  2   7   8
Affiliations
Case Reports

Successful desensitization protocol to alglucosidase and avalglucosidase alfa in a patient with infantile-onset Pompe disease

Miriam Gendive et al. Mol Genet Metab Rep. .

Abstract

Infantile-onset Pompe disease is a lysosomal disease characterized by cardiomyopathy and muscle weakness that, without specific treatment, is fatal within the first two years of life. We present the case of an infant who developed anaphylaxia to enzyme replacement therapy with alglucosidase-alfa. We provide a desensitization protocol to alglucosidase-alfa and, for the first time, a desensitization protocol to avalglucosidase-alfa, both delivered in a reasonable time of <6 h, and without any further reactions in the patient.

Keywords: Alglucosidase alfa; Anaphylaxia; Avalglucosidase alfa; Desensitization; Infantile-onset Pompe disease; Infusion associated reaction; Pompe disease.

PubMed Disclaimer

Conflict of interest statement

Javier de las Heras has received speaking and scientific consultancy fees from Sanofi.

References

    1. Tarnopolsky M., Katzberg H., Petrof B.J., Sirrs S., Sarnat H.B., Myers K., et al. Pompe disease: diagnosis and management. Evidence-based guidelines from a Canadian expert panel. Can. J. Neurol. Sci. 2016;43(4):472–485. - PubMed
    1. Kishnani P.S., Hwu W.L., Mandel H., Nicolino M., Yong F., Corzo D. A retrospective, multinational, multicenter study on the natural history of infantile-onset Pompe disease. J. Pediatr. 2006;148(5):671–676. - PubMed
    1. Kishnani P.S., Corzo D., Leslie N.D., Gruskin D., Van der Ploeg A., Clancy J.P., et al. Early treatment with alglucosidase alpha prolongs long-term survival of infants with Pompe disease. Pediatr. Res. 2009;66(3):329–335. - PMC - PubMed
    1. Kishnani P.S., Corzo D., Nicolino M., Byrne B., Mandel H., Hwu W.L., et al. Recombinant human acid [alpha]-glucosidase: major clinical benefits in infantile-onset Pompe disease. Neurology. 2007;68(2):99–109. - PubMed
    1. Gragnaniello V., Deodato F., Gasperini S., Donati M.A., Canessa C., Fecarotta S., et al. Immune responses to alglucosidase in infantile Pompe disease: recommendations from an Italian pediatric expert panel. Ital. J. Pediatr. 2022;48(1):41. - PMC - PubMed

Publication types

LinkOut - more resources